DaltonTx has launched an AI drug discovery platform which could help scientists “make better-informed decisions earlier in the discovery process”. The platform, called Dalton, seeks to integrate agentic AI, human expertise and experimental data into a continuous learning engine. DaltonTx says the platform links molecules, assays, models, experimental outcomes, project context and human decisions… Read More
CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology. Back has 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River. She will lead one of Sygnature’s in vivo pharmacology… Read More
Sygnature Discovery has announced the acquisition of Canada-based contract research organisation NuChem Sciences. The transaction expands Sygnature’s business operations into the North American market. Together, Sygnature Discovery and NuChem hope to combine the best of North American and UK operations. Marc Lebel, President and… Read More
